PDSB
Income statement / Annual
Last year (2024), PDS Biotechnology Corporation's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, PDS Biotechnology Corporation's net income was -$37.61 M.
See PDS Biotechnology Corporation,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$59.79 K
|
$57.33 K
|
$0.00
|
$0.00
|
$0.00
|
$98.41 K
|
$69.12 K
|
$182.92 K
|
$100.12 K
|
$53.12 K
|
| Gross Profit |
-$59.79 K
|
-$57.33 K
|
$0.00
|
$0.00
|
$0.00
|
-$98.41 K
|
-$69.12 K
|
-$183.00 K
|
-$100.00 K
|
-$53.12 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$22.57 M
|
$27.76 M
|
$29.43 M
|
$11.25 M
|
$7.92 M
|
$6.10 M
|
$830.74 K
|
$34.31 M
|
$24.83 M
|
$17.84 M
|
| General & Administrative Expenses |
$0.00
|
$15.02 M
|
$12.24 M
|
$10.18 M
|
$6.79 M
|
$0.00
|
$14.29 M
|
$17.66 M
|
$14.69 M
|
$8.66 M
|
| Selling & Marketing Expenses |
$0.00
|
$264.00 K
|
$0.00
|
$0.00
|
$183.37 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$13.70 M
|
$15.28 M
|
$12.24 M
|
$10.18 M
|
$6.98 M
|
$9.31 M
|
$14.29 M
|
$17.66 M
|
$14.69 M
|
$8.66 M
|
| Other Expenses |
$0.00
|
$1.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$12.74 B
|
$0.00
|
-$163.46 K
|
$0.00
|
| Operating Expenses |
$36.26 M
|
$43.05 M
|
$41.67 M
|
$21.44 M
|
$14.90 M
|
$15.41 M
|
$3.65 M
|
$51.97 M
|
$39.51 M
|
$26.50 M
|
| Cost And Expenses |
$36.32 M
|
$43.05 M
|
$41.67 M
|
$21.44 M
|
$14.90 M
|
$15.51 M
|
$30.36 M
|
$51.97 M
|
$39.51 M
|
$26.50 M
|
| Interest Income |
$2.52 M
|
$2.90 M
|
$935.18 K
|
$4.35 K
|
$55.01 K
|
$353.49 K
|
$871.88 K
|
$700.90 K
|
$212.30 K
|
$9.08 K
|
| Interest Expense |
$4.67 M
|
$4.21 M
|
$1.32 M
|
$0.00
|
$0.00
|
$33.56 K
|
$1.43 M
|
$2.18 M
|
$1.20 M
|
$816.49 K
|
| Depreciation & Amortization |
$59.79 K
|
$57.33 K
|
$86.00
|
$5.36 K
|
$15.61 K
|
$98.41 K
|
$69.12 K
|
$182.92 K
|
$100.12 K
|
$53.12 K
|
| EBITDA |
-$33.75 M |
-$40.09 M |
-$40.74 M |
-$21.43 M |
-$14.89 M |
-$7.25 M |
-$3.58 M |
-$51.08 M |
-$39.36 M |
-$28.32 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$2.16 M
|
-$1.30 M
|
-$381.34 K
|
$4.35 K
|
$55.01 K
|
$8.13 M
|
$0.00
|
$0.00
|
-$259.65 K
|
-$2.69 M
|
| Income Before Tax |
-$38.48 M
|
-$44.35 M
|
-$42.05 M
|
-$21.43 M
|
-$14.85 M
|
-$7.38 M
|
-$3.84 M
|
-$53.45 M
|
-$40.67 M
|
-$29.19 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$869.17 K
|
-$1.41 M
|
-$1.20 M
|
-$4.52 M
|
$0.00
|
-$381.51 K
|
-$2.78 M
|
-$2.59 M
|
$0.00
|
-$1.11 M
|
| Net Income |
-$37.61 M
|
-$42.94 M
|
-$40.85 M
|
-$16.92 M
|
-$14.85 M
|
-$7.00 M
|
-$40.87 M
|
-$50.86 M
|
-$38.82 M
|
-$28.08 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-1.03 |
-1.39 |
-1.43 |
-0.66 |
-0.89 |
-1.44 |
-26.16 |
-33.47 |
-26.9 |
-20.02 |
| EPS Diluted |
-1.03 |
-1.39 |
-1.43 |
-0.66 |
-0.89 |
-1.44 |
-10.25 |
-33.47 |
-26.9 |
-20.02 |
| Weighted Average Shares Out |
$36.45 M
|
$30.95 M
|
$28.60 M
|
$25.60 M
|
$16.75 M
|
$4.87 M
|
$166.87 K
|
$1.52 M
|
$1.44 M
|
$1.40 M
|
| Weighted Average Shares Out Diluted |
$36.45 M
|
$30.95 M
|
$28.60 M
|
$25.60 M
|
$16.75 M
|
$4.87 M
|
$3.99 M
|
$1.52 M
|
$1.44 M
|
$1.40 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
